A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40 mg modified-release capsules versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea.
Randomized controlled studies of combination therapies in rosacea are limited.Evaluate efficacy and safety of combining ivermectin 1% cream (IVM) and doxycycline 40 mg modified-release capsules∗ (DMR) versus IVM and placebo (PBO) for treatment of severe rosacea.This 12-week, multicenter, randomized,...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2020
|
| Sorozat: | JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
82 No. 2 |
| doi: | 10.1016/j.jaad.2019.05.063 |
| mtmt: | 30746290 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/20074 |
| LEADER | 02680nab a2200361 i 4500 | ||
|---|---|---|---|
| 001 | publ20074 | ||
| 005 | 20201214151611.0 | ||
| 008 | 201214s2020 hu o 0|| zxx d | ||
| 022 | |a 0190-9622 | ||
| 024 | 7 | |a 10.1016/j.jaad.2019.05.063 |2 doi | |
| 024 | 7 | |a 30746290 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a zxx | ||
| 100 | 1 | |a Schaller Martin | |
| 245 | 1 | 2 | |a A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40 mg modified-release capsules versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. |h [elektronikus dokumentum] / |c Schaller Martin |
| 260 | |c 2020 | ||
| 300 | |a 336-343 | ||
| 490 | 0 | |a JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY |v 82 No. 2 | |
| 520 | 3 | |a Randomized controlled studies of combination therapies in rosacea are limited.Evaluate efficacy and safety of combining ivermectin 1% cream (IVM) and doxycycline 40 mg modified-release capsules∗ (DMR) versus IVM and placebo (PBO) for treatment of severe rosacea.This 12-week, multicenter, randomized, investigator-blinded, parallel-group comparative study randomized adult subjects with severe rosacea (Investigator's Global Assessment [IGA]=4) to either IVM and DMR (combination arm) or IVM and PBO (monotherapy).A total of 273 subjects participated. IVM and DMR displayed superior efficacy in reduction of inflammatory lesions (-80.3% vs. -73.6% for monotherapy, p=0.032) and IGA score (p=0.032). Combination therapy had a faster onset of action as of week 4; it significantly increased the number of subjects achieving IGA 0 (11.9% vs. 5.1%, p=0.043)† and 100% lesion reduction (17.8% vs. 7.2%, p=0.006) at week 12. Both treatments reduced the Clinician's Erythema Assessment score, stinging/burning, flushing episodes, Dermatology Life Quality Index and ocular signs/symptoms, and were well-tolerated.The duration of study prevented evaluation of potential recurrences or further improvements.Combining IVM and DMR can produce faster responses, improve response rates, and increase patient satisfaction in severe rosacea. | |
| 700 | 0 | 1 | |a Kemény Lajos |e aut |
| 700 | 0 | 1 | |a Havlickova Blanka |e aut |
| 700 | 0 | 1 | |a Jackson Mark J. |e aut |
| 700 | 0 | 1 | |a Ambroziak Marcin |e aut |
| 700 | 0 | 1 | |a Lynde Charles |e aut |
| 700 | 0 | 1 | |a Gooderham Melinda |e aut |
| 700 | 0 | 1 | |a Remenyik Éva |e aut |
| 700 | 0 | 2 | |a Del Rosso James |e aut |
| 700 | 0 | 2 | |a Weglowska Jolanta |e aut |
| 700 | 0 | 2 | |a Chavda Rajeev |e aut |
| 700 | 0 | 2 | |a Kerrouche Nabil |e aut |
| 700 | 0 | 2 | |a Dirschka Thomas |e aut |
| 700 | 0 | 2 | |a Johnson Sandra |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/20074/1/61-s2.0-S0190962219308679-main.pdf |z Dokumentum-elérés |